JP2024517953A5 - - Google Patents
Info
- Publication number
- JP2024517953A5 JP2024517953A5 JP2023570085A JP2023570085A JP2024517953A5 JP 2024517953 A5 JP2024517953 A5 JP 2024517953A5 JP 2023570085 A JP2023570085 A JP 2023570085A JP 2023570085 A JP2023570085 A JP 2023570085A JP 2024517953 A5 JP2024517953 A5 JP 2024517953A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr3
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163187371P | 2021-05-11 | 2021-05-11 | |
| US63/187,371 | 2021-05-11 | ||
| PCT/US2022/028520 WO2022240833A1 (en) | 2021-05-11 | 2022-05-10 | Alpha 5 beta 1 integrin binding agents and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517953A JP2024517953A (ja) | 2024-04-23 |
| JP2024517953A5 true JP2024517953A5 (https=) | 2025-05-23 |
Family
ID=84028833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023570085A Pending JP2024517953A (ja) | 2021-05-11 | 2022-05-10 | アルファ５ベータ１インテグリン結合剤及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240279345A1 (https=) |
| EP (1) | EP4337698A4 (https=) |
| JP (1) | JP2024517953A (https=) |
| KR (1) | KR20240021162A (https=) |
| CN (2) | CN117980334A (https=) |
| AU (1) | AU2022273290A1 (https=) |
| CA (1) | CA3218656A1 (https=) |
| IL (1) | IL308406A (https=) |
| WO (1) | WO2022240833A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024102980A1 (en) * | 2022-11-11 | 2024-05-16 | Pasithea Therapeutics Corp. | Anti-alpha5 integrin antibodies and uses thereof |
| WO2025106724A2 (en) | 2023-11-15 | 2025-05-22 | Morphic Therapeutic, Inc. | USE OF ANTI-α5β1 ANTIBODIES IN THE TREATMENT OF PULMONARY HYPERTENSION AND HEART FAILURE |
| WO2025230866A1 (en) * | 2024-04-29 | 2025-11-06 | Pasithea Therapeutics Corp. | Anti-alpha5 integrin antibodies and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7285268B2 (en) * | 2002-11-26 | 2007-10-23 | Pdl Biopharma, Inc. | Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis |
| JP2007524605A (ja) * | 2003-04-03 | 2007-08-30 | ピーディーエル バイオファーマ，インコーポレイティド | インテグリンα５β１のインヒビターおよび組織顆粒化の制御のためのそれらの使用 |
| NZ615012A (en) * | 2006-03-21 | 2015-11-27 | Genentech Inc | Combinatorial therapy involving alpha5beta1 antagonists |
| WO2008127655A1 (en) * | 2007-04-13 | 2008-10-23 | Biogen Idec Ma Inc. | Anti-alpha 6 beta 4 integrin antibodies and uses therof |
| WO2009018226A2 (en) * | 2007-07-27 | 2009-02-05 | Facet Biotech Corporation | Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e) |
| US20200048618A1 (en) * | 2017-04-18 | 2020-02-13 | Autolus Limited | Cell |
| US11339221B2 (en) * | 2017-11-01 | 2022-05-24 | Tufts Medical Center, Inc. | Bispecific antibody constructs and methods of use |
-
2022
- 2022-05-10 IL IL308406A patent/IL308406A/en unknown
- 2022-05-10 EP EP22808176.6A patent/EP4337698A4/en active Pending
- 2022-05-10 AU AU2022273290A patent/AU2022273290A1/en not_active Abandoned
- 2022-05-10 US US18/559,703 patent/US20240279345A1/en active Pending
- 2022-05-10 CN CN202280049271.9A patent/CN117980334A/zh active Pending
- 2022-05-10 CA CA3218656A patent/CA3218656A1/en active Pending
- 2022-05-10 WO PCT/US2022/028520 patent/WO2022240833A1/en not_active Ceased
- 2022-05-10 CN CN202411049329.7A patent/CN119161478A/zh active Pending
- 2022-05-10 KR KR1020237041436A patent/KR20240021162A/ko active Pending
- 2022-05-10 JP JP2023570085A patent/JP2024517953A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022101693A5 (https=) | ||
| JP2020152735A5 (https=) | ||
| JP2024517953A5 (https=) | ||
| HRP20190605T1 (hr) | Protutijela anti-fxi i postupci njihove uporabe | |
| ME02371B (me) | Sastojci i postupci za dijagnstikovanje i tretman raka | |
| JP2024016024A5 (https=) | ||
| JP2020500834A5 (https=) | ||
| WO2015191934A2 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases | |
| JP2012532851A5 (https=) | ||
| JP2024532489A5 (https=) | ||
| JP2023549537A5 (https=) | ||
| JP2023518153A5 (https=) | ||
| JP2014524902A5 (https=) | ||
| JP2020522280A5 (https=) | ||
| JP2020522281A5 (https=) | ||
| JP2024541680A5 (https=) | ||
| IL276675B2 (en) | Anti-PD-1 antibodies and uses thereof | |
| JP2023543826A5 (https=) | ||
| JP2023549316A5 (https=) | ||
| JP2022521305A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| JP2024500512A5 (https=) | ||
| JP2023536631A5 (https=) | ||
| JP2023509215A5 (https=) | ||
| JP2023517754A5 (https=) | ||
| JP2025510642A5 (https=) |